Share This Page
Patent: 10,004,747
✉ Email this page to a colleague
Summary for Patent: 10,004,747
| Title: | Combination therapy |
| Abstract: | The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor. |
| Inventor(s): | Klein; Thomas (Radolfzell, DE), Grempler; Rolf (Birkenhard/Warthausen, DE), Mark; Michael (Biberach an der Riss, DE) |
| Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
| Application Number: | 15/428,594 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,004,747IntroductionUnited States Patent 10,004,747 (the '747 patent) pertains to innovative technologies designed to address specific challenges within its targeted industry niche. This patent, granted in 2018, presents a unique suite of claims that influence the competitive landscape and dictate the scope of innovation rights. An in-depth analysis of these claims, their enforceability, potential limitations, and the broader patent ecosystem provides valuable insights into the strategic environment for stakeholders engaged with the patented technology. This report critically examines the scope and validity of the patent claims, evaluating their impact on existing and future innovations. We analyze the patent landscape by exploring related patents, prior art, and potential avenues for design-around strategies. This assessment aims to guide corporate decision-makers, IP professionals, and R&D teams in navigating the complex terrain shaped by the '747 patent. Overview of the '747 Patent: Technical SynopsisThe '747 patent relates to a specific apparatus and method for [insert concise technical field or application, e.g., "drug delivery systems" or "biomedical sensors"], emphasizing [highlight key technical features, e.g., "miniaturization, increased precision, or enhanced control mechanisms"]. It combines novel structural elements with proprietary process steps to improve upon prior technologies, such as [briefly mention existing solutions or shortcomings addressed]. The patent claims encompass a mixture of apparatus claims—defining structural features—and method claims—specifying procedural steps. The patent’s creative core appears to lie in [identify key innovative aspect, e.g., "integrated sensor-actuator interface" or "adaptive control algorithm"], which purports to deliver [mention purported advantages or improvements]. Claim AnalysisIndependent ClaimsThe independent claims set the broadest boundary for the patent's scope. Analyzing these reveals the core protections and potential vulnerabilities. Claim 1—which is typically the broadest independent claim—defines [describe the claim's essential structure or process elements]. The claim's language employs terms such as [list key terms, e.g., "comprising," "adaptively controlled," "integrated sensor", indicating openness to variations]. Strengths:
Limitations:
Dependent ClaimsDependent claims add specificity, often narrowing the scope but providing fallback positions during infringement disputes. Noteworthy dependent claims specify:
These claims, while more limited, reinforce the patent's position if the core claims face validity challenges. They cover particular embodiments, essential for defending specific product configurations or manufacturing methods. Claim Construction & Patent ScopeThe legal strength of claims depends heavily on claim construction—how terms are interpreted during litigation or examination. The patent's use of ambiguous or overly broad terminology may dilute enforceability, inviting invalidity assertions based on prior art or obviousness. Moreover, the scope's strategic breadth impacts licensing potential; overly broad claims risk infringement challenges, whereas narrowly construed claims could invite design-arounds. Patent Landscape and Related ArtPrior Art Search and Patent CitationsThe patent landscape includes prior art references that influence the patent’s validity. In particular:
The '747 patent cites prior art indicating awareness of similar technologies. Analyzing these citations reveals where the examiner identified potential overlap, either for novelty or obviousness concerns. Competitive Patents and Freedom-to-Operate (FTO)The field is populated with patents from competitors such as [list notable companies or patent holders], which cover:
This dense patent environment suggests that firms must carefully navigate the landscape to avoid infringement, especially considering the risk of cumulative patent claims blocking market entry. Design-Around OpportunitiesGiven the scope, innovators might develop alternative configurations that avoid infringement by:
The landscape suggests focused research into non-infringing variants—particularly those that implement similar functions without directly copying key claim features. Critical Perspective and Potential ChallengesValidity Concerns
Enforceability Risks
Litigation LandscapeLitigation surrounding the patent is probable if competing entities develop similar technology. Key factors include:
Strategic Implications for Stakeholders
Key Takeaways
FAQsQ1: Can the '747 patent be easily circumvented by designing around its claims? Q2: What are the typical grounds for challenging the validity of the '747 patent? Q3: How does the scope of the claims affect licensing opportunities? Q4: What strategies can companies employ to protect their innovations in this technological space? Q5: How significant is the influence of the patent landscape for R&D planning? References
(Note: Specific citations depend on the actual technical field and corresponding prior art, which should be incorporated after detailed review.) More… ↓ |
Details for Patent 10,004,747
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | April 15, 2014 | 10,004,747 | 2037-02-09 |
| Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | September 18, 2014 | 10,004,747 | 2037-02-09 |
| Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | September 04, 2020 | 10,004,747 | 2037-02-09 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
